Press release
Hemophilia Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therap
DelveInsight's, "Hemophilia- Pipeline Insight, 2025," report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hemophilia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Hemophilia Pipeline constitutes 80+ key companies continuously working towards developing 80+ Hemophilia treatment therapies, analyzes DelveInsight.
Hemophilia Overview:
Hemophilia is a hereditary bleeding disorder caused by a deficiency of clotting factors-either factor VIII (in Hemophilia A) or factor IX (in Hemophilia B), which impairs the blood's ability to clot properly. This can lead to spontaneous bleeding or prolonged bleeding following injuries or surgical procedures. The severity of the condition correlates with the level of the clotting factor; lower levels result in more frequent and potentially severe bleeding episodes.
Although primarily inherited, hemophilia can occasionally develop later in life, especially in older adults or women during or after pregnancy. It is linked to mutations in genes located on the X chromosome that are responsible for producing clotting factors. Since males have only one X chromosome, they are more frequently affected, while females-who have two X chromosomes-are typically carriers unless both copies are defective, which is rare.
The two main forms are Hemophilia A and B, characterized by a lack of factor VIII and IX, respectively. Common symptoms include joint bleeding, easy bruising, bleeding from gums, and difficulty stopping bleeding even after minor injuries. Treatment generally involves regular infusions of the missing clotting factor, often administered at home, to control or prevent bleeding events.
Request for a detailed insights report on Hemophilia pipeline insights @ https://www.delveinsight.com/report-store/hemophilia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Hemophilia Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hemophilia Therapeutics Market.
Key Takeaways from the Hemophilia Pipeline Report
*
DelveInsight's Hemophilia pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Hemophilia treatment.
*
In December 2025, Be Biopharma launched its first-in-human Phase 1/2 clinical trial for BE-101, a B-cell treatment candidate for hemophilia B. The trial, called BeCoMe-9 (NCT06611436), is recruiting patients at two U.S. sites. BE-101 is a groundbreaking therapy aimed at addressing the unmet needs of hemophilia B patients, particularly those with frequent bleeding episodes. The two-part trial will assess the safety and clinical effectiveness of a single intravenous infusion of BE-101 in adults with moderately severe to severe hemophilia B.
*
In April 2025, Pfizer Inc. announced that the U.S. FDA approved BEQVEZ Trademark (fidanacogene elaparvovec-dzkt) for treating adults with moderate to severe hemophilia B. This approval is for patients on factor IX (FIX) prophylaxis therapy who have experienced life-threatening bleeding or recurrent serious spontaneous bleeding episodes and do not have neutralizing antibodies to AAVRh74var capsid. BEQVEZ is a one-time treatment that enables patients to produce FIX on their own, eliminating the need for regular intravenous FIX infusions.
*
In February 2025, Intellia Therapeutics and Regeneron announced plans to begin the first human trial of a CRISPR/Cas9-based Factor 9 (F9) gene-editing therapy for hemophilia B by mid-2025. This comes after the FDA approved the investigational new drug (IND) application filed by the companies.
*
Key Hemophilia companies such as Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk, and others are evaluating new drugs for Hemophilia to improve the treatment landscape.
*
Promising Hemophilia pipeline therapies in various stages of development include SerpinPC, Fitusiran, ASC 618, and others.
Hemophilia Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Hemophilia Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hemophilia market.
Download our free sample page report on Hemophilia pipeline insights [https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Hemophilia Emerging Drugs
*
SerpinPC: Centessa Pharmaceuticals
*
Fitusiran: Alnylam Pharmaceuticals
*
ASC 618: ASC Therapeutics
Hemophilia Companies
More than 80 prominent companies are actively developing treatments for Hemophilia. Among these, Alnylam Pharmaceuticals has the most advanced drug candidates, currently in Phase III of clinical development.
DelveInsight's report covers around 80+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Hemophilia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Hemophilia Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Hemophilia Therapies and Key Companies: Hemophilia Clinical Trials and advancements [https://www.delveinsight.com/report-store/hemophilia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Hemophilia Pipeline Therapeutic Assessment
- Hemophilia Assessment by Product Type
- Hemophilia By Stage
- Hemophilia Assessment by Route of Administration
- Hemophilia Assessment by Molecule Type
Download Hemophilia Sample report to know in detail about the Hemophilia treatment market @ Hemophilia Therapeutic Assessment [https://www.delveinsight.com/sample-request/hemophilia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Hemophilia Current Treatment Patterns
4. Hemophilia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Hemophilia Late-Stage Products (Phase-III)
7. Hemophilia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hemophilia Discontinued Products
13. Hemophilia Product Profiles
14. Hemophilia Key Companies
15. Hemophilia Key Products
16. Dormant and Discontinued Products
17. Hemophilia Unmet Needs
18. Hemophilia Future Perspectives
19. Hemophilia Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Hemophilia Pipeline Reports Offerings [https://www.delveinsight.com/report-store/hemophilia-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hemophilia-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-centessa-pharmaceuticals-alnylam-pharmaceuticals-asc-therapeutics-spark-therap]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hemophilia Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therap here
News-ID: 4105415 • Views: …
More Releases from ABNewswire

Best Deals on 2025 Kali Uchis Tour Tickets: Floor, Lower, and Club Seats with Pr …
Find the best deals on 2025 Kali Uchis tour tickets at CapitalCityTickets.com. Choose from floor, lower, and club seats-all available at discounted prices. Use promo code CITY10 at checkout for extra savings. Don't miss your chance to see Kali Uchis live-grab your tickets now and enjoy an unforgettable concert experience while saving big!
Get ready to experience the soulful and vibrant performances of Kali Uchis on her 2025 The Sincerely, Tour!…

Pure Parima Introduces New 'Lilac' Color to Ultra Percale Collection - Just in T …
Lumberton, New Jersey - Pure Parima [https://www.pureparima.com], the luxury bedding brand known for its certified Egyptian cotton and award-winning craftsmanship, is excited to announce the launch of a new, serene shade in its fan-favorite Ultra Percale Collection: Lilac [https://www.pureparima.com/collections/egyptian-cotton-sheets/products/hotel-collection-percale-sheet-set-in-white-100-els-giza-egyptian-cotton?variant=51382973497651].
Crisp, breathable, and irresistibly cooling, Ultra Percale is Pure Parima's go-to summer sheet-crafted from 100% Giza Egyptian cotton and designed with a one-over-one-under weave that delivers that hotel-style coolness night after night.…

Pure Parima Launches Best-Selling Silken Sateen TENCEL Trademark Sheet Set in Ne …
Lumberton, New Jersey - Just in time for summer, luxury bedding brand Pure Parima [https://www.pureparima.com] is expanding its award-winning Silken Sateen TENCEL Trademark Sheet Set collection with a fresh new color: Mist [https://www.pureparima.com/collections/egyptian-cotton-sheets/products/silken-sateen-tencel%E2%84%A2-sheet-set?variant=51382953705779]. Soft, breathable, and exceptionally cool to the touch, Mist is a calming, airy blue-gray shade designed to elevate your sleep space while keeping you cool all night long.
Crafted from a blend of long-staple Egyptian cotton and eco-friendly…

Lancofcu Helps Members Lower Monthly Payments Through Auto Loan Refinancing
Auto refinancing loans give you a second shot at structuring your vehicle financing in a way that better fits your current financial life. Maybe you took the dealer's financing because you needed the car fast. Maybe your credit score has improved. Maybe market rates have dropped, or you want to remove (or add) a co-borrower. Whatever the trigger, refinancing can lower your monthly payment, reduce total interest, shorten the term,…
More Releases for Hemophilia
Hemophilia Market Growth Analysis and Forecasts 2023-2032
Acumen Research and Consulting has recently published a research report on the Hemophilia Market for the forecast period of 2023 - 2032, wherein, the global market has been analyzed and assessed in an extremely comprehensive manner. The research report on the Hemophilia Market offers an extensive analysis of how the postoperative pain therapeutics landscape would evolve through 2032.
The research study on the Hemophilia Market analyzes key drivers upholding product sales…
Hemophilia Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Hemophilia Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Hemophilia Pipeline Report
• DelveInsight's Hemophilia pipeline…
Hemophilia Market Size Share Trends 2023-2030
Hemophilia Market Overview:
The global hemophilia market, which was valued at USD 11.7 billion in 2022, is expected to develop at a profitable rate and might reach USD 18 billion by 2030. It is anticipated that the hemophilia market would grow at a 5.9% CAGR from 2023 to 2030. A hereditary shortage of a coagulation factor causes hemophilia, which is characterized by insufficient blood-clotting proteins and delayed blood clotting.
Typically, medications, replacement…
Global Hemophilia Market Size & Trends
According to a new market research report published by Global Market Estimates, the global hemophilia market is projected to grow at a CAGR of 6.8% from 2023 to 2028.
During the forecast period, the global hemophilia market is anticipated to experience growth due to advancements in medical research, an increase in hemophilia incidence, and rising awareness and diagnosis.
Browse 147 Market Data Tables and 115 Figures spread through 163 Pages and…
Hemophilia Treatment Market | Global Industry Analysis 2023
The global hemophilia treatment market size was valued at USD 9,834.7 million in 2022 and is poised to grow at a significant CAGR of 5.2% during the forecast period 2023-29. The primary factors that drive the market are the growing prevalence of bleeding disorders mostly in men across the world, rising healthcare infrastructure, and increasing demand for efficient medication for the treatment.
View the detailed report description here https://www.precisionbusinessinsights.com/market-reports/haemophilia-treatment-market
The global hemophilia…
Acquired Hemophilia Treatment Market - Embracing Hope, Defying Hemophilia: Trans …
Newark, New Castle, USA: The "Acquired Hemophilia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Acquired Hemophilia Treatment Market: https://www.growthplusreports.com/report/acquired-hemophilia-treatment-market/7748
This latest report researches the industry structure,…